Back
ESC Premium Access

Impaired endogenous fibrinolysis in STEMI patients undergoing PPCI is an independent predictor of recurrent cardiovascular events -the RISK PPCI study

Session: No-reflow prevention and pathophysiology
Topic: Thrombosis, Platelets, and Coagulation
Speaker: Doctor M. Farag (Newcastle-Upon-Tyne, GB)
Event: ESC Congress 2018

Congress Presentation

About the speaker

Doctor Mohamed Farag

Freeman Hospital, Newcastle-Upon-Tyne (United Kingdom of Great Britain & Northern Ireland)
0 follower

4 more presentations in this session

No-reflow: prevention and pathophysiology - State of the art

Speaker: Doctor P. Wenzel (Mainz, DE)

Access
Slides
Video
Thumbnail

The modulation of miR-129-3p levels in coronary thrombi after primary PCI discloses a novel potential mechanism underlying the no reflow phenomenon

Speaker: Doctor S. De Rosa (Catanzaro, IT)

Access
Abstract
Thumbnail

Multicenter randomized clinical trial of the efficacy and safety of intravenous quercetin in patients with ST-elevation acute myocardial infarction

Speaker: Doctor S. Kozhukhov (Kiev, UA)

Access
Abstract
Thumbnail

The future of preventing reperfusion injury: achievable anytime soon?

Speaker: Doctor D. Pinto (Boston, US)

Access
Slides
Video
Thumbnail

Access the full session

No-reflow prevention and pathophysiology

Speakers: Doctor M. Farag, Doctor P. Wenzel, Doctor S. De Rosa, Doctor S. Kozhukhov, Doctor D. Pinto
Access
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb